论文部分内容阅读
作者报告１５０例自身免疫甲状腺疾病和２５例亚甲炎患者淋巴细胞亚群、甲状腺自身抗体和甲状腺激素测定结果。ＧＤ和ＨＴ未治组ＣＤ８＋、ＣＤ３＋下降、ＣＤ＋４／ＣＤ＋８比值和ＣＤ＋２０升高（Ｐ均＜０．０１）。ＧＤ未治组ＴＲＡｂ、ＴＭＡ和ＴＧＡ阳性率分别为９０．０％、６１．１％和５７．Ｏ％；ＨＴ未治组为２０．０％、８５．０％和７０．０％。亚甲炎组变化不明显。ＧＤ缓解组以上各指标均转向正常范围。ＧＤ未治组ＣＤ８＋与ＴＲＡｂ呈明显负相关，ＣＤ２０＋与ＴＲＡｂ呈显著正相关。ＣＤ８＋、ＣＤ２０＋与ＴＲＡｂ的检测是判断Ｇｒａｖｅｓ病发病机制及治疗效果和预后的可靠指标。
The authors report results of 150 thyroid autoimmune thyroid diseases and 25 lymphocyte subsets from patients with thyroiditis, thyroid autoantibodies and thyroid hormones. The levels of CD8 + and CD3 +, CD + 4 / CD + 8 and CD + 20 in GD and HT were significantly increased (all P <0.01). The positive rates of TRAb, TMA and TGA in GD group were 90.0%, 61.1% and 57% respectively. O%; HT group was 20.0%, 85.0% and 70.0%. There was no obvious change in the group of methylene blue inflammation. GD remission group of the above indicators are turned to the normal range. There was a significant negative correlation between CD8 + and TRAb in GD group and a significant positive correlation between CD20 + and TRAb. The detection of CD8 +, CD20 + and TRAb is a reliable indicator of the pathogenesis of Graves disease and the therapeutic effect and prognosis.